LANGER ROBERT

Row 1 · Balance 253,439

Row 2 · Balance Not disclosed

F1: Immediately exercisable, but subject to certain repurchase rights if the Reporting Person does not continue to serve as a director for up to three years following his February 12, 2017 appointment to the Issuer's board of directors. The Issuer's repurchase right with respect to 1/3 of the Reporting Person's shares will terminate following each full year of service on the Issuer's board of directors.

Row 1 · 2018-06-12 · Grant · Acquired 12,960 · Balance 12,960

F1: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Row 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Row 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Row 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Row 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Row 1 · 2020-05-05 · Conversion · Acquired 668 · Balance 15,167

F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.

Row 2 · 2020-05-05 · Conversion · Disposed 23,057 · Balance 0

F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.

Row 1 · 2024-05-06 · Grant · Acquired 7,557 · Balance 7,557

F1: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.

Row 1 · 2019-10-14 · Exercise / conversion · Acquired 7,500 · Balance 7,500

Row 2 · 2019-10-14 · Sale · Disposed 7,500 · Balance 0

F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.21 to $8.79, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Row 3 · 2019-10-14 · Exercise / conversion · Disposed 7,500 · Balance 120,000

F3: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter.

Row 1 · Balance 243,987

Row 2 · Balance Not disclosed

F1: The option vests and becomes exercisable as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter.

Row 3 · Balance Not disclosed

F2: The option vests and becomes exercisable as to 25% of the underlying securities on January 23, 2019 and in 36 equal monthly installments thereafter.

Row 4 · Balance Not disclosed

F3: The option vests and becomes exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter.

Row 1 · 2026-07-28 · Grant · Acquired 16,500 · Balance 821,025

F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

Row 2 · 2026-07-28 · Grant · Acquired 25,000 · Balance 25,000

F2: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.